APDN Announces $3.44M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
STONY BROOK, N.Y., January 31, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has entered into securities purchase agreements (SPAs) with certain existing institutional investors (collectively the “Holders”) for the issuance and sale of an aggregate of 5,644,061 of its shares of common [...]